ESTRO 2024 - Abstract Book

S1676

Clinical - Lung

ESTRO 2024

Keywords: Single-fraction SABR, Chest Wall Pain, NCTP

References:

1. Videtic GM, Paulus R, Singh AK, et al. Long-term Follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer. Int J Radiat Oncol. 2019;103(5):1077-1084. doi:10.1016/j.ijrobp.2018.11.051 2. Gensheimer MF, Gee H, Shirato H, et al. Individualized Stereotactic Ablative Radiotherapy for Lung Tumors: The iSABR Phase 2 Nonrandomized Controlled Trial. JAMA Oncol. Published online September 14, 2023. doi:10.1001/jamaoncol.2023.3495

3. Kimsey F, McKay J, Gefter J, et al. Dose-Response Model for Chest Wall Tolerance of Stereotactic Body Radiation Therapy. Semin Radiat Oncol. 2016;26(2):129-134. doi:10.1016/j.semradonc.2015.11.003

4. Moiseenko V, Marks LB, Grimm J, et al. A Primer on Dose-Response Data Modeling in Radiation Therapy. Int J Radiat Oncol Biol Phys. 2021;110(1):11-20. doi:10.1016/j.ijrobp.2020.11.020

1515

Digital Poster

Blood lymphocytes as a prognostic factor for stage III NSCLC with concurrent chemoradiation.

Yong-Hyub Kim, Sung-Ja Ahn, Taek-Keun Nam, Meesun Yoon, Jae-Uk Jeong

Chonnam National University Medical School, Chonnam National University Hwasun Hospital, Radiation Oncology, Jeollanamdo, Korea, Republic of

Purpose/Objective:

We aimed to identify blood lymphocytes as a prognostic factor for survival in patients with locally advanced stage III non-small cell lung cancer (NSCLC) treated with concurrent chemoradiotherapy (CCRT).

Material/Methods:

This is a secondary study of 196 patients enrolled in the Korean Radiation Oncology Group 0903 phase III clinical trial to evaluate the prognostic significance of circulating blood lymphocyte levels.

Results: